Ichiza elitsha lithoba ukusasazeka komhlaza wamabele

Uphononongo lwezonyango lwakutshanje lubonise ukuba iyeza elitsha lomhlaza wamabele linokuthoba esi sifo kangangeenyanga ezintathu kwaye libe neziphumo ebezingalindelekanga ezimbalwa.

Ichiza elivavanyayo, elaziwa ngokuba yi "TDM1," lisebenza ngokuchasene nolona hlobo lunobundlobongela lomhlaza webele, kwaye ichiza elithi "Herceptin" lixutywe nechemotherapy kwidosi enye, kwaye iimvavanyo zibonise ukuba ichiza elitsha lithintela umhlaza webele ukuba ungabi mbi kakhulu. iinyanga ezintathu xa kuthelekiswa nonyango oluqhelekileyo.Kwangaxeshanye, kunciphisa iziphumo ebezingalindelekanga zechemotherapy.

Eli chiza lithathwa njengelokuqala lohlobo lwalo lomhlaza wamabele kwaye lisebenza ngokuncamathela kwindawo yeseli ye-carcinogenic kwaye lithintele ukuba lingakhuli kwaye lisasazeke, ngelixa lisenza indlela yalo kwiseli ngaxeshanye kwaye likhupha ichemotherapy enetyhefu ngaphakathi. .

Kulingo lwabantu abaphantse babe li-2 abanomhlaza ophezulu we-HER1, abane kwalishumi abaguli baphendule kwi-TDMXNUMX, xa kuthelekiswa ngaphantsi kwesithathu sabo bebekunyango olusemgangathweni.

Unjingalwazi uPaul Ellis ovela kwiSibhedlele sikaGuy eLondon uthe: “Ezi ziphumo ziphawuleka ngenxa yokuba okokuqala ngqa kumhlaza wamabele, siye sakwazi ukuphucula kakhulu ukusebenza kakuhle ngelixa kwangaxeshanye sinciphisa uninzi lweziphumo ebezingalindelekanga ezinxulunyaniswa nechemotherapy.

Kwelakhe icala, uMlawuli weBritish Breast Cancer Research Society, uGqr. ULisa Wild Olu phononongo luphuhliso olulungileyo kwizigulane ezinomhlaza webele we-HER2 okwinqanaba eliphezulu okwangoku ezinokhetho olunyiniweyo lonyango.

Ngethamsanqa, umhlaza wamabele ngomnye womhlaza onokunyangeka ngokusisigxina ukuba ubonwe kwangethuba, kwaye le nto siyibiza ngawo onke amanina angaphezulu kweminyaka engama-25 ubudala.